Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

Inclusion Criteria

• •Diagnosed ulcerative colitis at least 90 days prior randomisation.
• •Men or women age 18 - 75 years.
• •Non-hospitalized patients with moderate-severe ulcerative colitis treated with stable background UC therapy (e.g. containing 5-aminosalicylates, and/or low dose of glucocorticosteroids, and/or purine analogue) prior to randomization.
• •Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from Day1.
• •Nonsterilized males or sterilized males who are ≤1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception.